JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2008; 51:2276-2285, doi:10.1016/j.jacc.2008.03.015 (Published online 8 April 2008).
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2008.03.015v1
51/23/2276    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Gheorghiade, M.
PubMed
Right arrow Articles by Gheorghiade, M.
Related Collections
Right arrowRelated Article

EXPEDITED PUBLICATION

Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent

A Randomized Controlled Trial in Patients Hospitalized With Heart Failure

Mihai Gheorghiade, MD, FACC*,*, John E.A. Blair, MD*, Gerasimos S. Filippatos, MD, FACC{dagger}, Cezar Macarie, MD{ddagger}, Witold Ruzyllo, MD§, Jerzy Korewicki, MD§, Serban I. Bubenek-Turconi, MD, Maurizio Ceracchi, MS||, Maria Bianchetti, PhD||, Paolo Carminati, MD||, Dimitrios Kremastinos, MD{dagger}, Giovanni Valentini, MD||, Hani N. Sabbah, PhD, FACC# for the HORIZON-HF Investigators

* Feinberg School of Medicine, Northwestern University, Chicago, Illinois
{dagger} University Hospital Attikon, Athens, Greece
{ddagger} National Institute of Cardiovascular Disorders, Bucharest, Romania
§ National Institute of Cardiology, Warsaw, Poland
CC Iliescu Heart Diseases Institute, Bucharest, Romania
|| Sigma-Tau, Pomezia (Rome), Italy
# Department of Medicine, Henry Ford Hospital, Detroit, Michigan.

Manuscript received February 28, 2008; revised manuscript received March 21, 2008, accepted March 21, 2008.

* Reprint requests and correspondence: Dr. Mihai Gheorghiade, Feinberg School of Medicine, Northwestern University, 201 East Huron Street, Galter 10-240, Chicago, Illinois 60611. (Email: m-gheorghiade{at}northwestern.edu).

Objectives: We examined the hemodynamic, echocardiographic, and neurohormonal effects of intravenous istaroxime in patients hospitalized with heart failure (HF).

Background: Istaroxime is a novel intravenous agent with inotropic and lusitropic properties related to inhibition of Na/K adenosine triphosphatase (ATPase) and stimulation of sarcoplasmic reticulum calcium ATPase.

Methods: One hundred twenty patients admitted with HF and reduced systolic function were instrumented with a pulmonary artery catheter within 48 h of admission. Three sequential cohorts of 40 patients each were randomized 3:1 istaroxime:placebo to a continuous 6-h infusion. The first cohort received 0.5 µg/kg/min, the second 1.0 µg/kg/min, and the third 1.5 µg/kg/min istaroxime or placebo.

Results: All doses of istaroxime lowered pulmonary capillary wedge pressure (PCWP), the primary end point (mean ± SD: –3.2 ± 6.8 mm Hg, –3.3 ± 5.5 mm Hg, and –4.7 ± 5.9 mm Hg compared with 0.0 ± 3.6 mm Hg with placebo; p < 0.05 for all doses). Istaroxime significantly decreased heart rate (HR) and increased systolic blood pressure (SBP). Cardiac index increased and left ventricular end-diastolic volume decreased significantly only with 1.5 µg/kg/min. On echocardiography, left ventricular end diastolic volume and deceleration time improved with 1.5 µg/kg/min. There were no changes in neurohormones, renal function, or troponin I. Adverse events were not life threatening and were dose related.

Conclusions: In patients hospitalized with HF, istaroxime improved PCWP and possibly diastolic function. In contrast to available inotropes, istaroxime increased SBP and decreased HR. (A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function [HORIZON-HF]; NCT00616161 [ClinicalTrials.gov] )

Abbreviations and Acronyms
  AHFS = acute heart failure syndromes
  CAD = coronary artery disease
  CI = cardiac index
  DBP = diastolic blood pressure
  HF = heart failure
  HR = heart rate
  LV = left ventricular
  LVEF = left ventricular ejection fraction
  PAC = pulmonary artery catheter
  PCWP = pulmonary capillary wedge pressure
  SBP = systolic blood pressure


Related Article

Istaroxime in Heart Failure: New Hope or More Hype
G. William Dec
J. Am. Coll. Cardiol. 2008 51: 2286-2288. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
G. W. Dec
Istaroxime in heart failure new hope or more hype.
J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2286 - 2288.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2008 by the American College of Cardiology Foundation.